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Abstract
Background: Fullerene compounds are known to possess antioxidant properties, a common property of chemical 
radioprotectors. DF-1 is a dendrofullerene nanoparticle with antioxidant properties previously found to be 
radioprotective in a zebrafish model. The purpose of this study was to evaluate the radioprotective effects of DF-1 in a 
murine model of lethal total body irradiation and to assess for selective radioprotection of normal cells versus tumor 
cells.
Methods: In vitro radioresponse was evaluated with clonogenic assays with human tumor cells and fibroblast lines in 
the presence of varying concentrations of DF-1 or vehicle. DNA double strand break induction and repair was 
evaluated with immunocytochemistry for γH2AX. Lethal total body irradiation was delivered with 137Cs after 
intraperitoneal delivery of DF-1 or vehicle control. Bone marrow hypoxia was evaluated with piminidazole uptake 
assessed by flow cytometry.
Results: DF-1 provided modest radioprotection of human cancer cell lines and fibroblast cell lines when delivered 
prior to irradiation (dose modifying factor or 1.1). There was no evidence of selective protection of fibroblasts versus 
tumor cells. Cells treated with DF-1 at radioprotective doses were found to have fewer γH2AX foci at 1 and 6 hours after 
irradiation compared to vehicle treated controls. The LD50/30 for C57Bl6/Ncr mice treated with a single 300 mg/kg 
dose of DF-1 pre-irradiation was 10.09 Gy (95% CI 9.58-10.26) versus 8.29 Gy (95% CI, 8.21-8.32) for control mice. No 
protective effects were seen with a single 200 mg/kg dose. No increase in pimonidazole uptake was appreciated in 
bone marrow of mice treated with DF-1 compared to vehicle controls.
Conclusions: DF-1 has modest activity as a radiation protector in vivo. There was no evidence of selective protection 
from irradiation of normal versus tumor cells with DF-1.
Background
Damage to normal tissues is a consequence of both thera-
peutic and accidental exposures to ionizing radiation.
Total body radiation exposures can result in lethality due
to hematopoetic damage, intestinal damage, and central
nervous system damage. Several compounds have been
described that protect tissues from exposure to ionizing
radiation. The majority of agents protect against acute
radiation damage are antioxidants which effectively scav-
enge free radicals, thus preventing indirect DNA damage,
the predominant cause of cell death after exposure to ion-
izing radiation. The search for compounds that can
reduce the deleterious effects of radiation are of interest
in the setting of therapeutic radiation for cancers and in
the setting of accidental or terrorism related exposures.
To categorize agents that alter normal tissue radiation
response, the terms radioprotectors, radiation mitigators,
and treatment have recently been adopted[1,2]. Chemical
radioprotectors exert their protective effects through
scavenging of free radicals[3]. A variety of compounds
that act as chemical radioprotectors have been described
including agents such as amifostine and other thiols,[4,5]
nitroxides, [6-8] polyphenols,[9] tocols,[10] ethyl pyru-
vate,[11] superoxide dismutase mimetics,[12,13], mela-
tonin and its homologues,[14] and other free radical
scavengers. (reviewed in [15]). In addition to antioxi-
dants, other compounds have been found to have radio-
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protective capabilities such as agents that inhibit p53 and
p73 function,[16]. Checkpoint kinase inhibitors,[17]
inhibitors of c-Abl,[18] and modulators of apoptosis[19]
have been found to have radioprotective capabilities.
(reviewed in [15]).
Carboxyfullerenes are potent antioxidants due to their
free radical scavenging ability[20]. The antioxidant nature
of fullerene derivatives have been exploited for a variety
of disease conditions characterized by chronic inflamma-
tion or free radical generation [21-25]. Prior studies have
shown that polyhydroxylated fullerenes can function as
radiation protectors [26-28]. Additional modifications in
the fullerene molecule side chains to enhance solubility
and resultant antioxidant capacity has been under-
taken[21]. One such compound is DF-1, a C60 dendrof-
ullerene nanoparticle with potent antioxidant
propertamifostineies[29]. DF-1 has previously been
shown to improve the survival of zebrafish after exposure
to ionizing radiation[28]. Little is known about the effects
of DF-1 as a radiation protector in mammals such as
mice. In addition, little is known about selectivity of DF-1
radioprotection in normal versus tumor tissue.
We found that human tumor cells and immortalized
fibroblasts are only protected at the highest achievable
concentrations of DF-1, although the magnitude of this
protection was small with dose modifying factors at a
surviving fraction of 0.1 of 1.1. Protection was only seen
when DF-1 was delivered prior to irradiation, a finding
suggestive of chemical radioprotection and consistent
with the known antioxidant property. Treatment of cells
with DF-1 prior to irradiation also led to a small but sig-
nificant reduction in DNA double strand breaks mea-
sured by γH2AX foci at one hour after irradiation,
supporting that DF-1 reduced the number of DNA dou-
ble strand breaks that occurred after irradiation. We also
determined that immediate pre-irradiation treatment
with DF-1 can protect mice from lethal total body irradi-
ation in a dose dependent fashion. The extent of this pro-
tection was significant at the highest dose of DF-1
delivered compared to controls, but was modest com-
pared to previously described radiation protectors. Based
on these results, our further evaluation of the radiopro-
tective capacity of fullerenes will focus on compounds
with enhanced solubility and antioxidant capacity that
may provide a clinically translatable method of radiopro-
tection.
Methods
Cell Lines and Treatment
The MiaPaCa2 (pancreatic adenocarcinoma) and DU145
(prostatic adenocarcinoma) cell lines were obtained from
the Division of Cancer Treatment and Diagnosis Tumor
Repository, NCI-Frederick (Frederick, Maryland). MRC5
(human fibroblast) were obtained from American Type
Culture Collection (Manassas, VA). Cells were cultured
in RPMI 1640 medium (Quality Biological, Gaithersburg,
Maryland) containing 2 mM L-glutamine, supplemented
with 5% (MiaPaCa-2) or 10% (DU145) fetal bovine serum
(Hyclone, Logan, Utah). Cells were maintained at 37°C,
5% CO2. DF-1, provided by Suma Partners, was reconsti-
tuted in a 1:1 solution of DMSO and PBS and stored at -
20°C. Cultures were irradiated using a Pantak (Solon,
OH) X-ray source at a dose rate of 1.55 Gy/min.
Clonogenic Assay
C e ll  cul t ur es  we r e  t ryps inized t o g en er a t e  a  si ngle  c e l l
suspension and a specified number of cells were seeded
into each well of six-well tissue culture plates. After
allowing 6 hours for attachment, the cells were incubated
with DF-1 at the indicated concentration of DMSO (vehi-
cle control) prior to irradiation. In some studies, DF-1
was delivered following irradiation in an alternative
schedule. Following irradiation, cells were incubated for
12 to 14 days. At that time colonies were stained with
crystal violet, the number of colonies containing at least
50 cells was determined, and the surviving fractions were
calculated. Survival curves were generated after normal-
izing for cytotoxicity generated by DF-1 alone for each
independent experiment. Data presented are the mean ±
SEM from at least three independent experiments. Dose
modifying factor (DMF) was determined from radiation
survival curves by taking the ratio of radiation doses at
the 10% survival level (DF-1 treated radiation dose
divided by the control radiation). DMF values > 1 indicate
protection.
Immunocytochemistry
Cells grown in tissue culture chamber slides were fixed
with 1% paraformaldehyde, permeabilized with 0.4% Tri-
ton X-100, and blocked with 2% bovine serum albumin
(BSA) in PBS. The cells were stained with anti-γH2AX
antibody (Millipore Corp., Billerica, MA), washed, and
incubated with fluorescence conjugated secondary anti-
bodies (Molecular Probes/Invitrogen,) and DAPI (Sigma-
Aldrich, St. Louis, MO). Slides were examined on a Leica
DMRXA fluorescent microscope (Wetzlar, Germany).
Images were captured by a Photometrics Sensys CCD
camera (Roper Scientific, Tucson, AZ) and imported into
IP Labs image analysis software package (Scanalytics,
Inc., Fairfax, VA). For each treatment condition, the total
number of γH2AX foci per cell was determined in at least
50 cells.
Mice
Ten to 12-week-old female C57/Bl6 Ncr mice (Fredrick
Labs, Frederick, MD) were used in these studies. Mice
were obtained at 6-8 weeks of age and caged in groups of
five or less. All animals were fed a diet of animal chowBrown et al. Radiation Oncology 2010, 5:34
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and water ad libitum. All animal studies were conducted
in accordance with the principles and procedures out-
lined in the NIH Guide for the Care and Use of Animals
was approved by the NCI Animal Care and Use Commit-
tee.
Toxicity Studies
Mice were weighed individually. DF-1 was delivered via
intraperitoneal (IP) injection at doses of 5, 15, 35,100,
200, 300 mg/kg. All IP injections were delivered in 100
μL. Survival was assessed daily for two weeks.
Total Body Irradiation
Mice were randomized in groups of 5 to total body irradi-
ation at graded doses following intra peritoneal (IP) injec-
tion of vehicle control (DMSO/PBS) or DF-1 at doses of
200 and 300 mg/kg. 15 minutes following IP injection
mice were transferred to plexiglass containers with holes
for ventilation. Two separate containers were placed in
the sample tray of the irradiator and mice were irradiated
with the indicated total body doses. A 137Cs Gamma Cell
40 (Nordion International, Kanata, Ontario, Canada) was
used as the ionizing radiation source. The irradiator was
calibrated with thermoluminescent dosimetry chips
implanted in phantom mice. The radiation dose was
determined according to previously described methodol-
ogy [30]. The dose rate used was 76.43 cGy/min. After
irradiation mice were returned to cages for observation.
Survival was assessed daily for 30 days after irradiation.
Evaluation of bone marrow hypoxia
Mice were injected IP with pimonidazole dissolved in
PBS at a dose of 60 mg/kg. Ten minutes later DF-1 (300
mg/kg) or vehicle control was delivered via IP injection.
Mice were euthanized via cervical dislocation three hours
following pimanidazole injection and bone marrow was
harvested from both femurs. Bone marrow was immedi-
ately cooled on wet ice and flushed with PBS through a 27
gauge needle. Following centrifugation at 1200 rpm cells
PBS was aspirated and cells were fixed in 4% paraformal-
dehyde at room temperature for 15 minutes. Following
fixation cells were washed with PBS and resuspended in
PBS containing 0.2% Triton-X 100 and incubated at room
temperature for 10 minutes. Cells were washed once in
PBS followed by resuspension in PBS containing 0.1%
bovine serum albumin.
Hypoxia was assessed with flow cytometric assay using
the Hypoxyprobe1 Plus Kit (HPI, Inc. Burlington, MA).
Briefly, cells were reacted with anti-pimonidazole mono-
clonal antibody, washed, and then reacted with fluores-
cein isothiocyanate-conjugated anti-mouse
immunoglobulin (Jackson ImmunoReserch Laboratories
Inc, West Grove, PA). Positive cells were detected by flow
cytometric analysis using a FACScan (BD Biosciences;
San Jose, CA), with at least 10,000 cells analyzed for each
set of conditions tested. Tumor cells maintained at nor-
moxic conditions and hypoxic conditions were fixed and
assayed as above as negative and positive controls). For
hypoxic in vitro assays, cells were incubated for 18 hours
with a closed non-vented cap.
Statistical Analysis
In vitro experiments were repeated three times and sta-
tistical analysis was done using a student's t-test. Data are
presented as mean ± SD. A probability level of P < 0.05
was considered significant. Statistical analyses of lethality
studies were performed using R bioconductor package (R
Development Core Team (2009) available at http://
www.R-project.org). Survival of mice after irradiation
was assessed by generalized logistic regression analysis
(GLM). LD50/30 and 95% confidence limits were deter-
mined from GLM curve fitting of the 30 day mortality
d a t a  f i t t e d  t o  l o g i t  c u r v e s .  T h e  d o s e s  w e r e  l o g  t r a n s -
formed to improve the overall fit. Differences between
survival curves were assessed by 2-tailed log likelihood
ratio test of the logistic model. Prognostic relevance of
the treatment in comparison to control group was
assessed by Kaplan-Meier survival analysis using R statis-
tical package. To test the difference between the survival
curves, log rank test was used.
Results
In vitro studies
To determine the effects of DF-1 on tumor cell and fibro-
blast radiosensitivity, clonogenic survival analysis was
performed in the MRC5, DU145, and MiaPaCa-2 cell
lines. DF-1 was delivered at 10 μM and 100 μM final con-
centration immediately prior to irradiation. As shown in
figure 1, DF-1 treatment at 10 μM had no effect on cellu-
lar radiosensitivity with DMFs of 1.0 for the MRC5 and
DU145 cell lines. Pretreatment with 100 μM DF-1
resulted in DMF of 1.1 for both the DU145 and MRC5
cell lines. No protection was observed with MiaPaCa-2
cells at 100 μM DF-1.
To determine the importance of timing of DF-1 deliv-
ery on observed effect, the duration of treatment with
DF-1, the duration of pre-IR treatment, and the duration
of post-IR treatment were varied in single radiation dose
clonogenic assays. Pre-IR treatment of up to 6 hours did
not improve the efficacy of protection compared to
immediate pre-IR treatment (data not shown) and post-
treatment exposures of up to 16 hours did not alter clo-
nogenic survival compared to drug removal immediately
after IR (data not shown) suggesting that exposure during
radiation was critical for protection. Based on these pre-
liminary data additional complete clonogenic assays were
performed to allow calculation of DMF with pre-treat-
ment exposure times of one hour or less. Clonogenic sur-
vival analysis was performed in DU145 cells with DF-1Brown et al. Radiation Oncology 2010, 5:34
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Page 4 of 9
delivery occurring 60 minutes pre-IR, 30 minutes IR,
immediately post-IR, 30 minutes post-IR, and 60 minutes
post-IR. For these studies DF-1 was delivered at a final
concentration of 100 μM. Relative protection with DF-1
was only observed if DF-1 was delivered prior to irradia-
tion (figure 2).
To further investigate the cellular processes through
which DF-1 protects from ionizing radiation, we focused
on the DU145 cell line. DNA damage repair is an impor-
tant component of radiation-induced cytotoxicity. Many
radioprotectors exhibit their protective effect by scaveng-
ing free radicals and thus reducing indirect DNA damage.
As a measure of radiation-induced DNA damage, we
evaluated induction of nuclear foci of phosphorylated
histone H2AX (γH2AX), which has been established as a
sensitive indicator of DNA double strand breaks (DSBs)
with the resolution of foci corresponding to DSB repair.
Cells were exposed to DF-1 for 30 minutes and irradiated
(4 Gy) as in the cell survival experiments, and γH2AX
foci were counted at 1, 6 and 24 hrs post IR. Exposure of
cells to DF-1 at 10 μM had no significant effect on the
number of γH2AX foci at 1, 6, and 24 hours compared to
vehicle controls (figure 3). In contrast, a significant
r e d u c t i o n  i n  t h e  n u m b e r  o f  γ H 2 A X  f o c i  p e r  c e l l  w a s
observed after treatment with 100 μM DF-1 at 1 and 6
hours after IR compared to treatment with either vehicle
or 10 μM DF-1, suggesting that DF-1 impacts the imme-
diate DNA damage after irradiation. At 24 hrs the num-
ber of γH2AX foci per cell was similar in the vehicle and
both DF-1 groups suggesting that DNA DSB repair was
not impacted by DF-1 treatment.
Toxicity of DF-1 via intraperitoneal injection
The maximum tolerated intraperitoneal dose of DF-1 was
not reached in C57Bl6/Ncr mice. We were unable to fur-
ther concentrate the agent in a suitable concentration of
DMSO for in vivo studies beyond 350 mg/kg. At all dose
levels, mice were observed to be hypokinetic beginning at
approximately 5 minutes after injection. The duration of
this effect was longer at higher doses lasting for up to 30
minutes in the 350 mg/kg group and for as short as 5
minutes in the 50 mg/kg group. This hypokinetic period
was not observed in mice injected with vehicle controls.
Mice treated at all doses survived through the two week
observation period maintaining weight and without obvi-
ous untoward effects.
Figure 1 The effects of DF-1 on cellular radiosensitivity. Cell lines MRC5, DU145, and MiaPaCa-2 were exposed to DF-1 (100 μM and 10 μM) or 
vehicle control immediately prior to irradiation with graded doses of X-rays. Colony-forming efficiency was determined 10 to 14 days later and survival 
curves generated after normalizing for toxicity of DF-1 alone. The data represent the mean of three independent experiments. PE, plating efficiency 
with DF-1; DMF, dose modifying factor. Points, mean; bars, ± SE.
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In vivo radioprotection
Treatment of mice with 300 mg/kg of DF-1 by intraperi-
toneal injection 15 minutes prior to irradiation provided
a survival advantage at 30 days. Deaths in the control
group usually occurred after day 10 at doses of 8.5 Gy and
lower. At doses of 9 Gy and higher deaths began as early
as one week. Treatment with DF-1 at 300 mg/kg
increased the 30 day survival of mice treated with total
body irradiation. The LD 50/30 was determined by using
doses ranging between 6 and 11 Gy with each data point
Figure 2 The effects of the timing of DF-1 treatment on cellular radiosensitivity. DU145 cells were exposed to DF-1 at 100 μM or vehicle control 
at the indicated times in relation to irradiation with graded doses of X-rays. Colony-forming efficiency was determined 10 to 14 days later and survival 
curves generated after normalizing for toxicity with DF-1 alone. The data represent the mean of three independent experiments. DMF, dose modifying 
factor. Points, mean; bars, ± SE.
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Figure 3 The effects of DF-1 on DNA double strand breaks. To investigate the effects of DF-1 on formation and repair of DNA double strand breaks 
after irradiation, γ-H2AX foci were evaluated by immunocytochemistry in DU145 cells. A) The number of γ-H2AX foci at 1 and 4 hrs after irradiation (4 
Gy) in cells treated with 100 μM DF-1 was significantly less than that observed in cells treated with 10 μM DF-1 or vehicle alone. Columns, mean; bars, 
SE; *, p < 0.05. B) Representative images from stained cells.
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representing at least 10 mice. The LD50/30 for 300 mg/kg
was 10.09 Gy (95% CI 9.58-10.26) versus 8.29 Gy (95% CI,
8.21-8.32) for control mice (figure 4). This effect repre-
sents a dose modifying factor (radiation dose which
caused 50% lethality at 30 days in DF-1 treated group
divided by the dose of radiation which caused 50% lethal-
ity at 30 days in the control group) of 1.22. The difference
in surviving fraction between the DF-1 treated mice (300
mg/kg) and the vehicle treated mice was significant (p =
0.01). Kaplan-Meier analysis revealed a significant benefit
to 300 mg/kg DF-1 compared to vehicle control and 200
mg/kg at the 9 Gy dose (figure 5).
Effects of DF-1 on bone marrow hypoxia
A number of chemical radioprotectors have been shown
t o  i n d u c e  b o n e  m a r r o w  h y p o x i a ,  w i t h  b o n e  m a r r o w
hypoxia correlating to protective effect[31]. We hypothe-
sized that the hypokinetic period after DF-1 administra-
tion could possibly be related to hypotension and as a
result bone marrow hypoxia. To evaluate if the hypokien-
tic time period after DF-1 administration was associated
with bone marrow hypoxia which could contribute to
radioprotection, we evaluated pimonidazole uptake in
marrow of mice treated with DF-1. No significant differ-
ence in the proportion of hypoxic bone marrow cells was
observed with this technique suggesting marrow protec-
tion via hypoxia secondary to hypotension was not a
probable secondary mechanism of action in vivo (table 1).
Discussion
Fullerene compounds have been studied extensively for
their antioxidant properties[21,32-34]. Few studies have
reported the ability of these agents to protect against
exposure to ionizing radiation. As the chemical proper-
ties, such as solubility and antioxidant capacity, can vary
depending on the modification of the fullerene struc-
ture,[21,35] a large number of candidate radioprotectors
exist in this class that remain untested. Prior studies of
fullerene compounds as radioprotectors have included an
evaluation of C3, a regioisomer of water soluble carboxy-
fullerene, which was found to protect murine hematopo-
etic cells from irradiation ex vivo[26]. The magnitude of
protection  ex vivo was somewhat greater than that
observed in vitro in the current study for normal cells,
however these models are not directly comparable. The
degree of tumor cell protection observed in vitro is simi-
lar with the results presented here.
The polyhydroxylated fullerene C60(OH)24 was previ-
ously evaluated as a protector of radiation and compared
to amifostine in rats[27]. This study evaluated histologic
measures of radiation damage but did not evaluate lethal-
ity. A recent study of the polyhydroxylated fullerene
C60(OH)24 in a murine model suggested that chronic dos-
ing of fullerene compounds can protect from lethal total
body exposures[36]. This study employed dosing for two
weeks prior to potentially lethal irradiation of 8 Gy.
Because only a single dose of irradiation was evaluated in
this study, an LD50/30 cannot be calculated, thus pre-
cluding a determination of the DMF obtained with this
compound and preventing comparisons to the efficacy of
DF-1.
As  m os t  l e t h a l  t o t a l  bod y  e x pos u r es  a r e  e x pect ed  t o
occur without weeks of warning, a knowledge of the pro-
tective capacity of immediate pre-exposure dosing is
important. The current study describes the ability of DF-
1, a dendrofullerene compound, to protect mice from
lethal total body radiation exposures. Only a modest pro-
tective effect was observed with DF-1 in the in vitro set-
ting. Because of the differences in methodology of the
above studies, it is impossible to adequately compare the
efficacy of DF-1 to other fullerene compounds in vitro.
Amifostine (WR-2721) is perhaps the best studied
radioprotector and has been approved for clinical use.
Prior studies with amifostine have shown a concentration
dependent dose modifying factor for the LD50/30 for
total body exposures to ionizing radiation. The DMF for
Figure 4 The effects of DF-1 on 30 day survival in mice exposed to 
lethal irradiation. C57Bl6/Ncr mice were randomized into three groups: 
DF-1 200 mg/kg, DF-1 300 mg/kg, and vehicle control. DF-1 was deliv-
ered via intraperitoneal injection in a single dose of 15 minutes prior to 
irradiation at the indicated doses. Mice were observed and lethality was 
scored at 30 days. Each group contained at least 10 mice. Horizontal bars, 
95% confidence interval (CI); LD50/30, dose of radiation resulting in le-
thality in 50% of mice at 30 days; DMF, dose modifying factor.
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amifostine delivered as a single dose prior to a single frac-
tion total body gamma irradiation ranges from 1.25 for 40
mg/kg to as high as 2.78 for 400 mg/kg.)[5]. This is supe-
rior to the DMF of 1.2 seen in this study with 300 mg/kg
of DF-1. When considering the DMF for an agent,
another important consideration is the toxicity of the
agent.
The degree of toxicity of amifostine in mice correlates
with the degree of radioprotection.)[5]. We observed a
hypokinetic period after DF-1 administration, but these
mice fully recovered, thus our maximum tolerated dose
was defined by solubility limitations. It is possible that
higher doses if achievable and tolerable may provide
additional protection. This is also true of the in vitro
radioprotection observed here where maximum doses
were limited by solubility. Additional modifications to the
fullerene compounds may enhance solubility, drug deliv-
ery, and tissue concentrations, thereby enhancing effec-
tiveness. Given the high molecular weight of many
fullerene compounds, direct comparisons of concentra-
tion may be difficult and mg dosing as opposed to μM
dosing may provide a better opportunity for comparison.
W e found no evidence of selectivity of normal tissue
protection compared to tumor protection in our in vitro
studies. Amifostine is known to have preferential protec-
tive capabilities in normal tissues due to a differential in
the uptake in normal compared to tumor tissues [37]. It is
unknown if DF-1 has this preferential uptake or other
characteristics that would make it or similar compounds
an attractive agent for further clinical development in the
setting of therapeutic radiation.
A common mechanism of action of chemical radiopro-
tectors is protection of DNA from indirect damage to
DNA through free radical interactions. Fullerene deriva-
tives are known to enter the nucleus of cells[38]. It is pos-
sible that they may also exert radioprotective effects
Figure 5 The effects of DF-1 on survival during the first 30 days after lethal irradiation in mice. C57Bl6/Ncr mice were randomized into three 
groups: DF-1 200 mg/kg, DF-1 300 mg/kg, and vehicle control. DF-1 was delivered via intraperitoneal injection in a single dose of 15 minutes prior to 
irradiation at the indicated doses. Mice were observed and lethality was scored daily for the first 30 days. Kaplan Meier analysis was performed for mice 
receiving 8 Gy (A) and 9 Gy (B) of total body irradiation. Each treatment group contained at least 10 mice.
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Table 1: The effects of DF-1 on bone marrow hypoxia measured with pimonidazole.
Averaged mean fluorescence Relative mean fluorescence
Normoxic cells (in vitro)4 6 . 8 1 . 0
Hypoxic cells (in vitro) 89.88 1.92
Vehicle treated mice 5.18 1.0
DF-1 treated mice 5.83 1.13Brown et al. Radiation Oncology 2010, 5:34
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through scavenging free radicals in the nucleus of cells,
thereby preventing the primary lethal event of radiation,
DNA double strand breaks. The protection we observed
correlated with a decrease in γH2AX foci at 1 and 6 hours
after radiation, suggesting that a reduction of indirect
DNA damage may be the primary mechanism of action of
DF-1 in vitro. Cai et al. reported that chronic fullerene
dosing prior to total body irradiation exposure was asso-
ciated with a decreased immune and mitochondrial dys-
function as well as antioxidant levels in the liver and
spleen [36]. Acute exposures to fullerene compounds are
unlikely to result in rapid increases in antioxidant levels
in the liver and spleen selectively. However, it is likely that
scavenging of free radicals and a reduction of DNA dam-
age from irradiation is one of the mechanisms of protec-
tion in our study.
The small discrepancy between the extent of protection
in vitro and the in vivo suggest that alteration of a physio-
logic process may be partially responsible for the
observed effect. Based on the hypokinesis treated with
DF-1 and the possible hypoperfusion observed in the ani-
mals treated with the combination of DF-1 and total body
irradiation we evaluated the possibility that bone marrow
hypoxia occurs after exposure to DF-1. Hypoxia is known
to protect cells and from irradiation[39] and could be
responsible for both the effect seen and the discrepancy
between in vitro and in vivo effects. No difference was
observed in hypoxia in the marrow of mice treated with
DF-1 compared to vehicle controls suggesting that bone
marrow hypoxia is not a mechanism by which DF-1
exerts is radioprotective effects.
Based on the data presented here, the fullerene com-
pounds are of potential interest in the setting of radiation
protection, although DF-1 may not be the best candidate
for further development based on the limitations we
described. Identification of compounds with superior sol-
ubility and anti-oxidant capacity should be undertaken in
the future and evaluated in this setting. Additional explo-
rations into mechanisms of efficacy are warranted when
compounds with substantial activity are identified.
The equilibration and clearance of fullerene com-
pounds are dependent on structure[21]. In general fuller-
enes are known to equilibrate rapidly after intraperitoneal
delivery[21]. Clearance occurs over the course of
days[21]. Concentration in liver, spleen, and bone have
been reported at time points over one hour[21]. Addi-
tional modifications to the fullerene compounds may the-
oretically allow targeting of specific organs for protection.
This may be particularly useful for organs with relatively
low tolerance to irradiation such as lung, kidney, and
liver.
Conclusions
Acute pre-total body irradiation exposure to DF-1 has
modest activity as a radiation protector in vivo. Pre-irra-
diation treatment with DF-1 reduces DNA double strand
breaks consistent with a chemical radioprotector. There
is no evidence of selective protection from irradiation of
normal versus tumor cells with DF-1.
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